Our single-center retrospective study focused on Stage IV Clear Cell Renal Cell Carcinoma patients who received first-line sunitinib therapy and found that baseline tumor apparent diffusion coefficient value derived from 3T diffusion weighted imaging showed different level in different response group. Baseline tumor ADC value also had significant correlation with progression-free survival. Patients with higher tumor ADC value had significantly longer progression-free survival. Basline tumor ADC can be a potential predictor in assessing targeted therapy response of Stage IV ccRCC.
This abstract and the presentation materials are available to members only; a login is required.